8-K: Aptose Biosciences Announces $8.4 Million Public Offering and $4 Million Private Placement

Aptose Biosciences has announced an $8.4 million public offering and a concurrent $4 million private placement with Hanmi Pharmaceutical to fund clinical trials and working capital.

Summary

• Aptose Biosciences has priced a public offering of 4,912,280 common shares at $1.71 per share, with each share including a warrant to purchase another share at the same price.
• The gross proceeds from the public offering are expected to be approximately $8.4 million before deducting expenses.
• Underwriters have a 30-day option to purchase an additional 736,842 common shares and warrants.
• Aptose also announced a concurrent private placement with Hanmi Pharmaceutical for $4 million, with Hanmi purchasing shares at $1.90 each, an 11% premium over the public offering price.
• Hanmi will own 19.97% of Aptose's outstanding common shares after the private placement.
• Hanmi will also receive warrants to purchase common shares at $1.71 per share.
• The private placement fulfills Hanmi's remaining investment obligations under a previous agreement.
• The public offering is expected to close around January 30, 2024, and the private placement around January 31, 2024, both subject to customary closing conditions.
• The net proceeds will be used to support clinical trials for tuspetinib, manufacture clinical supplies, and for general corporate purposes.
• Newbridge Securities Corporation is the sole book-running manager for the public offering and placement agent for the private placement.

Sentiment

Score: 7

Explanation: The announcement is generally positive, securing necessary funding for clinical trials and demonstrating strategic investor confidence. However, the dilutive nature of the public offering and the inherent risks of biotech development temper the overall sentiment.

Positives

• The capital raise will provide funding for the clinical development of tuspetinib.
• The private placement with Hanmi Pharmaceutical demonstrates strategic investor confidence.
• Hanmi's investment at a premium price validates the company's value.
• The company has secured funding for manufacturing clinical supplies.
• The company has secured funding for working capital and general corporate purposes.

Negatives

• The public offering is priced at $1.71 per share, which may be seen as dilutive to existing shareholders.
• The company is relying on exemptions from TSX standards for the offering.

Risks

• The closing of the public offering and private placement are subject to customary closing conditions.
• The use of proceeds may change due to market conditions or other reasons.
• The company's future success depends on the clinical development of tuspetinib.
• There are inherent risks and uncertainties in the biotechnology industry.

Future Outlook

The company intends to use the net proceeds from the offerings to support clinical trials for tuspetinib, manufacture clinical supplies, and for working capital and general corporate purposes. The company is subject to risks and uncertainties and cannot guarantee the accuracy of forward-looking statements.

Management Comments

• Aptose is developing precision medicines for unmet needs in oncology, with a focus on hematology.
• The company's lead product, tuspetinib, is being studied in a Phase 1/2 trial for relapsed or refractory acute myeloid leukemia.

Industry Context

This announcement is typical for clinical-stage biotech companies that require capital to fund ongoing research and development. The private placement with a strategic partner like Hanmi Pharmaceutical is a positive signal for the company's prospects.

Comparison to Industry Standards

• The public offering price of $1.71 per share is relatively low, which is not uncommon for clinical-stage biotech companies.
• The 11% premium paid by Hanmi in the private placement is a positive sign, indicating confidence in the company's prospects.
• Other companies in the biotech sector, such as Xencor and Iovance Biotherapeutics, have also recently raised capital through public offerings and private placements.
• The use of proceeds for clinical trials and manufacturing is standard practice in the industry.

Related Party Transactions

• The private placement with Hanmi Pharmaceutical is a related party transaction.

Stakeholder Impact

• Shareholders will experience dilution from the public offering.
• The company will have additional capital to fund operations and clinical trials.
• The company's long-term success depends on the clinical development of tuspetinib.

Next Steps

• The public offering is expected to close on or about January 30, 2024.
• The private placement is expected to close on or about January 31, 2024.
• The company will use the proceeds to support clinical trials for tuspetinib, manufacture clinical supplies, and for working capital.

Key Dates

Keywords

public offering, private placement, Aptose Biosciences, Hanmi Pharmaceutical, tuspetinib, clinical trials, hematologic malignancies, oncology, capital raise, warrants